Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Ticker
$BLTE
Sector
Primary listing
Employees
41
Headquarters
Website
BLTE Metrics
BasicAdvanced
$5.4bn
-
-$2.54
-1.19
-
Price and volume
Market cap
$5.4bn
Beta
-1.19
52-week high
$200.00
52-week low
$56.10
Average daily volume
211k
Financial strength
Current ratio
33.706
Interest coverage (TTM)
-50,687.50%
Profitability
EBITDA (TTM)
-101.187
Management effectiveness
Return on assets (TTM)
-12.99%
Return on equity (TTM)
-18.93%
Valuation
Price to book
6.83
Price to tangible book (TTM)
6.83
Growth
Earnings per share change (TTM)
86.18%
3-year earnings per share growth (CAGR)
46.10%
BLTE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs